
## Appendix 1



## (adapted from SIGN 96 and NICE CG126)

1. Beta blocker Green or calcium channel blocker 🛢 Green

(Decide which to use based on comorbidities, contraindications and the person's preference.)



= if drug treatment not tolerated/ symptoms not satisfactorily controlled

2. Consider switching to the alternative option, or using a combination of the

When combining a calcium channel blocker with a beta blocker, use a dihydropyridine calcium channel blocker (first choice amlodipine) as rate-limiting CCB are cautioned with beta blockers.

3. Add isosorbide mononitrate



- 4. Add nicorandil Green or under the direction of cardiology, ivabradine Amber
- Nicorandil should not be used in patients with prior or risk factors for GI ulceration
- Ivabradine can only be used in patients in sinus rhythm with HR ≥ 75bpm and must not be used with rate limiting CCB

5. Consultant cardiologists can consider ranolazine Amber 375mg M/R twice daily.

Only to be used if all other treatments are not tolerated/patient still inadequately controlled, and unsuitable for surgical revascularisation.

## **Prescribing points**

- Do not offer a third anti-anginal drug to people whose stable angina is controlled with two anti-anginal drugs.
- Consider adding a third anti-anginal drug only when the person's symptoms are not satisfactorily controlled with two anti-anginal drugs and the person is waiting for revascularisation or revascularisation is not considered appropriate or acceptable
- Review the person's response to treatment, including any side effects, 2-4 weeks after starting or changing drug treatment.
- Patients whose symptoms are not controlled on maximum therapeutic doses of two drugs should be considered for referral to a cardiologist.

Green - General Prescribing Amber - GP under direction of Cardiology

Prepared by - Joanne McGeoghie (Specialist Clinical Pharmacist)

Approved by – Stuart Hutcheon (Clinical Lead for Cardiology)

Prepared - April 2017 Review - April 2019